DongKoo Bio&Pharma Co. Ltd (006620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.20 Billion ≈ $810.96K USD) by net assets (₩110.66 Billion ≈ $74.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DongKoo Bio&Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 006620 total debt and obligations for a breakdown of total debt and financial obligations.
DongKoo Bio&Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etrend Hightech
TWO:3567
|
0.028x |
|
Big 5 Sporting Goods Corporation
NASDAQ:BGFV
|
-0.258x |
|
Memscap Regpt
PA:MEMS
|
0.048x |
|
West Coast Silver Ltd
AU:WCE
|
-1.634x |
|
Korea SPAC 2
KQ:206400
|
-0.010x |
|
Green Plus Co. Ltd
KQ:186230
|
0.075x |
|
Next Entertainment World Co. Ltd
KQ:160550
|
0.138x |
|
nTels Co. Ltd
KQ:069410
|
-0.030x |
Annual Cash Flow Conversion Efficiency for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 006620 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩105.33 Billion ≈ $71.38 Million |
₩17.34 Billion ≈ $11.75 Million |
0.165x | +407.23% |
| 2023-12-31 | ₩110.44 Billion ≈ $74.85 Million |
₩3.59 Billion ≈ $2.43 Million |
0.032x | -80.29% |
| 2022-12-31 | ₩102.11 Billion ≈ $69.20 Million |
₩16.82 Billion ≈ $11.40 Million |
0.165x | -7.88% |
| 2021-12-31 | ₩100.12 Billion ≈ $67.85 Million |
₩17.90 Billion ≈ $12.13 Million |
0.179x | +126.00% |
| 2020-12-31 | ₩94.65 Billion ≈ $64.14 Million |
₩7.49 Billion ≈ $5.08 Million |
0.079x | -33.16% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.05 Million |
₩10.14 Billion ≈ $6.87 Million |
0.118x | +1178.70% |
| 2018-12-31 | ₩72.10 Billion ≈ $48.86 Million |
₩-791.20 Million ≈ $-536.19K |
-0.011x | -104.36% |
| 2017-12-31 | ₩37.74 Billion ≈ $25.58 Million |
₩9.51 Billion ≈ $6.44 Million |
0.252x | -55.89% |
| 2016-12-31 | ₩22.05 Billion ≈ $14.94 Million |
₩12.59 Billion ≈ $8.53 Million |
0.571x | -79.00% |
| 2015-12-31 | ₩2.55 Billion ≈ $1.73 Million |
₩6.93 Billion ≈ $4.70 Million |
2.719x | -- |
About DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more